|
Normal
|
Disease state |
|
|
Monocyte
|
Cell type |
|
|
None
|
Compound treatment |
|
|
A549
|
Cell line |
|
|
Homo sapiens
|
Organism |
|
|
Stromal cell
|
Cell type |
|
|
PC3
|
Cell line |
|
|
Peripheral blood
|
Organism part |
|
|
Fibroblast
|
Cell type |
|
|
Macaca mulatta
|
Organism |
|
|
Pan troglodytes
|
Organism |
|
|
Bone marrow
|
Organism part |
|
|
MK886
|
Compound treatment |
|
|
Caco-2
|
Cell line |
|
|
Placebo
|
Compound treatment |
|
|
Primary
|
Disease staging |
|
|
Lymph node metastasis
|
Disease staging |
|
|
SW480
|
Cell line |
|
|
SW620
|
Cell line |
|
|
FLAP
|
Compound treatment |
|
|
Control
|
Compound treatment |
|
|
17beta-estradiol
|
Compound treatment |
|
|
Lymph node
|
Organism part |
|
|
Dendritic cell
|
Cell type |
|
|
Macrophage
|
Cell type |
|
|
HNRPA2B
|
Compound treatment |
|
|
Organism_part
|
Material type |
|
|
Cell
|
Material type |
|
|
ERalpha transfected
|
Genotype |
|
|
Lung
|
Organism part |
|
|
HL-60
|
Cell line |
|
|
MCF7
|
Cell line |
|
|
Synovial fluid
|
Organism part |
|
|
White blood cells
|
Organism part |
|
|
SsMCF7
|
Cell line |
|
|
Kidney
|
Organism part |
|
|
Caudate nucleus
|
Organism part |
|
|
PCep4 control vector transfect...
|
Gene modification |
|
|
ETat plasmid transfection
|
Gene modification |
|
|
Endothelial cell
|
Cell type |
|
|
Cerebellum
|
Organism part |
|
|
Epilepsy
|
Disease state |
|
|
Clear cell sarcoma of the kidn...
|
Disease state |
|
|
Primary bone marrow CD34+ stem...
|
Cell type |
|
|
Jurkat
|
Cell line |
|
|
Lipopolysaccharide
|
Compound treatment |
|
|
T4aNxMx
|
Disease staging |
|
|
KSHV latent infection
|
Disease state |
|
|
ERbeta transfected
|
Genotype |
|
|
Malignant melanoma
|
Disease state |
|
|
Wilms' tumor
|
Disease state |
|
|
Affymetrix Labeling
|
Protocol type |
|
|
Heregulin
|
Compound treatment |
|
|
Monocyte at intermediate diffe...
|
Cell type |
|
|
4OH-tamoxifen
|
Compound treatment |
|
|
Psoriatic lesional biopsy
|
Clinical info |
|
|
Uninvolved biopsy
|
Clinical info |
|
|
Endometrioid carcinoma
|
Disease state |
|
|
Glutamine
|
Compound treatment |
|
|
TIVE
|
Cell line |
|
|
Enzo Labeling
|
Protocol type |
|
|
U266
|
Cell line |
|
|
HPL1
|
Cell line |
|
|
T3aNxM1
|
Disease staging |
|
|
Kaposi's sarcoma
|
Disease state |
|
|
Epidermal keratinocyte
|
Cell type |
|
|
SkinEthic keratinocyte
|
Cell type |
|
|
Colorectal adenocarcinoma
|
Disease state |
|
|
T47-D
|
Cell line |
|
|
CD3+ CD4+ CD8- CD45RA+ CD62L+
|
Phenotype |
|
|
Naive T cell
|
Cell type |
|
|
HaCaT
|
Cell line |
|
|
Duchenne muscular dystrophy
|
Disease state |
|
|
GLI56
|
Cell line |
|
|
MDA-MB-231
|
Cell line |
|
|
MCF-7
|
Cell line |
|
|
CD3- CD4+ CD8-
|
Phenotype |
|
|
Intrathymic T progenitor cell
|
Cell type |
|
|
Fetal bovine serum in media
|
Growth condition |
|
|
Kaposi's sarcoma-associated he...
|
Infection |
|
|
Serum starvation + thymidine b...
|
Growth condition |
|
|
Oligodendroglioma
|
Disease state |
|
|
ATM knockdown
|
RNAi |
|
|
MCF10A
|
Cell line |
|
|
Grade III
|
Tumor grading |
|
|
Methotrexate
|
Compound treatment |
|
|
Multiple myeloma
|
Disease state |
|
|
Lymphatic endothelial cell
|
Cell type |
|
|
Stage II
|
Disease staging |
|
|
Hypericin incubated, not irrad...
|
Growth condition |
|
|
Hypericin incubated, irradiate...
|
Growth condition |
|
|
CD3int CD4+ CD8+
|
Phenotype |
|
|
Double positive thymocyte
|
Cell type |
|
|
Skeletal muscle
|
Organism part |
|
|
Vulvar intraepithelial neoplas...
|
Disease state |
|
|
Metastatic
|
Disease staging |
|
|
SCH
|
Cell line |
|
|
Stage I
|
Disease staging |
|
|
Primary gastric tumor
|
Organism part |
|
|
Relapse 1; ER status ER+; brai...
|
Clinical info |
|
|
Dimethyl sulfoxide
|
Compound treatment |
|
|
2-(3,4,5-trimethoxy-phenylamin...
|
Compound treatment |
|
|
Burkitt's lymphoma
|
Disease state |
|
|
BDCA3+ dendritic cell
|
Cell type |
|
|
Keratinocyte
|
Cell type |
|
|
HTERT/HPVE6 transfection
|
Gene modification |
|
|
LacZ control
|
RNAi |
|
|
Whole blood
|
Organism part |
|
|
Adrenal cortex cell
|
Cell type |
|
|
HTERT/HPVE6/HPVE7/SV40t transf...
|
Gene modification |
|
|
Control - interferon-gamma
|
Compound treatment |
|
|
CD3high CD4+ CD8-
|
Phenotype |
|
|
Single positive thymocyte
|
Cell type |
|
|
GLI60
|
Cell line |
|
|
Tumor
|
Organism part |
|
|
Papillary thyroid carcinoma
|
Disease state |
|
|
Presymptomatic
|
Disease staging |
|
|
Adipocyte
|
Cell type |
|
|
Adrenal neuroblast
|
Cell type |
|
|
Astrocytoma
|
Disease state |
|
|
T84
|
Cell line |
|
|
HTERT/HPVE6/HPVE7/SV40t/hRas t...
|
Gene modification |
|
|
Tonsil
|
Organism part |
|
|
Erythrocyte
|
Cell type |
|
|
U87
|
Cell line |
|
|
U373
|
Cell line |
|
|
Teratozoospermia
|
Disease state |
|
|
Normospermic
|
Disease state |
|
|
Cancer13
|
Replicate |
|
|
293
|
Cell line |
|
|
Lymphoid tissue
|
Organism part |
|
|
Native skin
|
Cell type |
|
|
GLI72
|
Cell line |
|
|
Uninfected control
|
RNAi |
|
|
Primary lymphatic endothelial ...
|
Cell type |
|
|
Total_RNA
|
Material type |
|
|
Polysome-associated RNA
|
Material type |
|
|
Granulocyte
|
Cell type |
|
|
T-cell lymphoblastic lymphoma
|
Disease state |
|
|
HTERT transfection
|
Gene modification |
|
|
IL-22
|
Compound treatment |
|
|
Well-functioning transplant
|
Clinical info |
|
|
TaN0M0
|
Disease staging |
|
|
Benign prostatic hyperplasia
|
Disease state |
|
|
Prostate carcinoma
|
Disease state |
|
|
Primary cells
|
Cell line |
|
|
IL-20
|
Compound treatment |
|
|
Ischemic cardiomyopathy
|
Disease state |
|
|
Estrogen receptor 1 negative; ...
|
Test result |
|
|
Superficial transitional cell ...
|
Disease state |
|
|
Hematopoietic stem cell
|
Cell type |
|
|
Adipose tissue-derived stem ce...
|
Cell type |
|
|
Epidermal growth factor
|
Compound treatment |
|
|
Benign nevi
|
Disease state |
|
|
Mannitol
|
Compound treatment |
|
|
Neutrophil
|
Cell type |
|
|
Primary fibroblast
|
Cell type |
|
|
Heart
|
Organism part |
|
|
Benign
|
Disease staging |
|
|
Actinomycin D
|
Compound treatment |
|
|
Human papilloma virus positive
|
Disease state |
|
|
Human papilloma virus negative
|
Disease state |
|
|
IMP(1,3)A
|
RNAi |
|
|
Frontal cortex, superior motor...
|
Organism part |
|
|
Pongo pygmaea
|
Organism |
|
|
Johnsen score count 3.2: Serto...
|
Histology |
|
|
Relapse 0; ER status ER-; brai...
|
Clinical info |
|
|
Plasmacytoid dendritic cell
|
Cell type |
|
|
Unsynchronized
|
Growth condition |
|
|
Breast carcinoma
|
Disease state |
|
|
Brain
|
Organism part |
|
|
NCI-H929
|
Cell line |
|
|
Prostate
|
Organism part |
|
|
Granulocyte macrophage-colony ...
|
Compound treatment |
|
|
Ultraviolet light
|
Light |
|
|
Grade II
|
Tumor grading |
|
|
ITS medium with albumin-bound ...
|
Growth condition |
|
|
ITS medium
|
Growth condition |
|
|
Postprandial lipid micelles in...
|
Growth condition |
|
|
Inter-prandial lipid micelles ...
|
Growth condition |
|
|
Heat-killed HL60 cell lysate
|
Infection |
|
|
Cyclosporin A, mycophenolate m...
|
Clinical treatment |
|
|
Sirolimus, mycophenolate mofet...
|
Clinical treatment |
|
|
Bacterial endotoxin
|
Compound treatment |
|
|
Invasive ductal carcinoma
|
Histology |
|
|
Normal
|
Disease staging |
|
|
Spermatocyte
|
Cell type |
|
|
Cardiac myocyte
|
Cell type |
|
|
BT474
|
Cell line |
|
|
Skin
|
Organism part |
|
|
Monocyte-derived osteoclast
|
Cell type |
|
|
Female
|
Sex |
|
|
Male
|
Sex |
|
|
Seminiferous tubule
|
Organism part |
|
|
Selenium
|
Compound treatment |
|
|
Acute promyelocytic leukemia
|
Disease state |
|
|
U937
|
Cell line |
|
|
Uterine fibroid
|
Disease state |
|
|
Mutant fumarate hydratase
|
Genotype |
|
|
Control
|
Genotype |
|
|
Mock
|
RNAi |
|
|
Lin- CD34-
|
Phenotype |
|
|
T4aN2M0
|
Disease staging |
|
|
BL41K3
|
Cell line |
|
|
BJABK3
|
Cell line |
|
|
T-cell acute lymphoblastic leu...
|
Disease state |
|
|
All-trans retinoic acid
|
Compound treatment |
|
|
T3aN0Mx
|
Disease staging |
|
|
IL-24
|
Compound treatment |
|
|
HTERT/HPVE6/HPVE7 transfection
|
Gene modification |
|
|
N/a
|
Test result |
|
|
M-CSF
|
Compound treatment |
|
|
ITM-ST
|
Cell line |
|
|
Bronchial epithelial cell
|
Cell type |
|
|
Nickel(II) chloride hexahydrat...
|
Compound treatment |
|
|
T47D
|
Cell line |
|
|
U0126
|
Compound treatment |
|
|
SKMEL5
|
Cell line |
|
|
Control - IL-1b
|
Compound treatment |
|
|
CodeLink Labeling
|
Protocol type |
|
|
Relapse 1; ER status ER-; brai...
|
Clinical info |
|
|
Not applicable
|
Histology |
|
|
Without bone lytic lesion
|
Clinical info |
|
|
With bone lytic lesion
|
Clinical info |
|
|
ERalpha/beta transfected
|
Genotype |
|
|
T3bN1M0
|
Disease staging |
|
|
MM1
|
Cell line |
|
|
Lin- CD34+
|
Phenotype |
|
|
T2N0M0
|
Disease staging |
|
|
Vanadium pentoxide
|
Compound treatment |
|
|
HMEC184
|
Cell line |
|
|
Plasma cell
|
Cell type |
|
|
B lymphocyte
|
Cell type |
|
|
IL-19
|
Compound treatment |
|
|
Testis
|
Organism part |
|
|
Crohn's disease
|
Disease state |
|
|
Epithelial cell
|
Cell type |
|
|
Typical disease progression
|
Clinical history |
|
|
Empty vector
|
Gene modification |
|
|
HGF stimulation
|
Growth condition |
|
|
Mercaptopurine
|
Compound treatment |
|
|
Pons
|
Organism part |
|
|
Prostate cancer
|
Disease state |
|
|
M2 macrophage
|
Cell type |
|
|
Ewing family tumor
|
Disease state |
|
|
Neuroblastoma
|
Disease state |
|
|
No induction
|
Protocol type |
|
|
Dermatomyositis
|
Disease state |
|
|
Endothelial cell + pericyte
|
Cell type |
|
|
Trichostatin A
|
Compound treatment |
|
|
Non-lung
|
Organism part |
|
|
Obesity
|
Disease state |
|
|
Acute malaria, natural infecti...
|
Disease state |
|
|
DMSO
|
Vehicle |
|